BioMarin (BMRN) Pharmaceutical Stock Climbs On Positive Study Data

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) BioMarin Pharmaceutical stock is up today after releasing positive results with regard to the Phase 2 proof-of-concept and dose funding study of BMN 111, also known as vosoritide. Today, we’ll take a look at the results to see what investors are so excited about, talk about what we’ve seen in … Read more

Synergy Pharmaceuticals (SGYP) Stock Continues To Climb On Study Results

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) Synergy Pharmaceuticals climbed nicely following the release of information regarding a recent gastrointestinal study. Following the release of the data, the stock climbed in a big way yesterday, and today, it looks like the climb is continuing. So below, we’ll discuss the results of the study that have investors so … Read more

Gilead Sciences (GILD) Stock | Will It Break Resistance On This Run?

Gilead Sciences, Inc. (NASDAQ: GILD) Gilead Sciences stock is continuing an incredible run toward the top. The leader in HIV and HCV treatments has may have had a tough time a couple of months back, but as it continues to control the HCV market, despite AbbVie Inc’s (NYSE: ABBV) attempts to take control, the stock … Read more

MannKind (MNKD) Stock Is Up | Will It Last?

MannKind Corporation (NASDAQ: MNKD) MannKind has been a very interesting stock to watch over the past several months. After a soft launch of Afrezza didn’t move quite as quickly as Goldman Sachs wanted to see earlier in the year, the company’s stock was downgraded; leading to a swift decline that turned into months long downtrends. … Read more

Gilead Sciences (GILD) Stock Presents A Buying Opportunity

Gilead Sciences, Inc. (NASDAQ: GILD) Gilead Sciences is one of my favorite stocks to follow; and I’d be willing to bet that I’m not the only person that feels that way. With a stronghold on the hepatitis C and HIV markets, Gilead proves to be stronger and stronger with each passing month; and yesterday, the … Read more

MannKind (MNKD) Stock Reaches Support | Time For Gains

MannKind Corporation (NASDAQ: MNKD) After a bullish run that lasted about 3 weeks, MannKind has had a tough week in the market this week. However, as I’ve mentioned since the stock started downtrends, I wasn’t too concerned. As a matter of fact, I saw the declines as an opportunity; and it looks like today is … Read more

MannKind (MNKD) Stock Continues Falling | When Will We See Gains

MannKind Corporation (NASDAQ: MNKD) MannKind Corporation has been an incredibly interesting stock to watch recently. After struggling a few months back thanks to a Goldman Sachs downgrade; a research note from Jefferies sent the stock back in bullish mode over the past couple of weeks. However, this week has been a bit of a different … Read more

MannKind (MNKD) Stock | Why I’m Not Worried About Today’s Declines

MannKind Corporation (NASDAQ: MNKD) MannKind has been a very interesting stock to watch over the past few months. First, there was the Goldman Sachs downgrade that sent the stock spiraling down, then there was the Jefferies survey that sent the stock climbing. Now today, the stock is down yet again; but I’m not concerned. As … Read more

MannKind (MNKD) Stock Is Exploding | You’re Not Too Late For Gains!

MannKind Corporation (NASDAQ: MNKD) If you follow CNA Finance or my writing elsewhere, you probably already know that MannKind is and has been one of my favorite biotech stocks for quite some time. While I may have gotten a bit of backlash for my opinion on MNKD in the past; it’s clear that recently, investors … Read more